<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aberrant hypermethylation of CpG islands in the promoter region of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor and other important genes in neoplastic cells of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has been demonstrated to be one of the mechanisms for epigenetic loss of gene function </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we analyzed promoter hypermethylation of the following genes in 49 cases of primary gastric <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PGL</z:e>): ATM, p16INK4a(CDKN2A), hMLH1, MGMT, DAPK, and CDH1(ECAD) </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PGL</z:e> cases studied included 26 (53%) cases of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), 12 (25%) cases of extranodal marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>), 7 (14%) cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> with large cell transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), 1 (2%) case of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), one (2%) case of Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), one case (2%) of lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LPL) and one case (2%) of peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Available pathologic data regarding to extragastric involvement at the time of resection of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PGLs</z:e> were reviewed and correlated </plain></SENT>
<SENT sid="4" pm="."><plain>Promoter hypermethylation was detected in 6 of 49 (12.2%) cases for ATM; 13 of 49 (26.5%) for p16INK4a, 19 of 49 (38.8%) for hMLH1; 22 of 49 (44.9%) for MGMT; 27 of 49 (55.1%) for DAPK and 16 of 49 (32.7%) for CDH1 </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 85% of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PGLs</z:e> had promoter hypermethylation in at least one of these genes </plain></SENT>
<SENT sid="6" pm="."><plain>With different histologic subtypes, promoter hypermethylation of DAPK, hMLH1, and CDH1 genes occurred in 70%, 42%, and 42% respectively for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, which appeared to be higher than combined <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> subgroup </plain></SENT>
<SENT sid="7" pm="."><plain>Approximately 81% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PGLs</z:e> demonstrated H. pylori <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> by immunohistochemistry </plain></SENT>
<SENT sid="8" pm="."><plain>H. pylori status did not appear to be statistically correlated with promoter hypermethylation of the genes </plain></SENT>
<SENT sid="9" pm="."><plain>Of 37 PGL cases, 19 cases had extragastric involvement at the time of resection, indicating relatively higher stage disease </plain></SENT>
<SENT sid="10" pm="."><plain>The frequencies of promoter methylation in those cases were 58% for DAPK, 42% for hMLH1, 37% for CDH1, 26% for p16INK4a and 11% for ATM respectively </plain></SENT>
<SENT sid="11" pm="."><plain>The promoter methylation at MGMT gene was significantly higher in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PGLs</z:e> without extragastric involvement (61%) as compared to those with extragastric involvement (26%) </plain></SENT>
</text></document>